Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.

MLA

Vartak, Richa, et al. “Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.” Pharmaceutical Research, vol. 39, no. 11, Nov. 2022, pp. 2745–59. EBSCOhost, https://doi.org/10.1007/s11095-022-03184-3.

APA

Vartak, R., Saraswat, A., Yang, Y., Chen, Z.-S., & Patel, K. (2022). Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera. Pharmaceutical Research, 39(11), 2745–2759. https://doi.org/10.1007/s11095-022-03184-3

Chicago

Vartak, Richa, Aishwarya Saraswat, Yuqi Yang, Zhe-Sheng Chen, and Ketan Patel. 2022. “Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.” Pharmaceutical Research 39 (11): 2745–59. doi:10.1007/s11095-022-03184-3.